La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Senhwa Biosciences Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Jin-Ding Huang

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDG	n/a
Durée du mandat du directeur général	2.6yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2yrs
Durée moyenne du mandat des membres du conseil d'administration	7.2yrs

Mises à jour récentes de la gestion

Recent updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

Jan 19

PDG

Jin-Ding Huang

2.6yrs

Titularisation

Dr. Jin-Ding Huang, PhD, serves as Director since March 1, 2022 and Chief Executive Officer at Senhwa Biosciences, Inc. since 2022 and serves as its Chief Scientific Officer since 2022 until 2022 and as it...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Sarah Chang	Vice President & CFO	10.4yrs	NT$8.76m	pas de données
Jin-Ding Huang	CEO & Director	2.6yrs	pas de données	pas de données
Joanne Lo	Acting Chief Operating Officer & Business Development Director	1.5yrs	pas de données	pas de données
Jason Huang	Chief Medical Officer	less than a year	pas de données	pas de données

2.0yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de 6492 est considérée comme expérimentée (ancienneté moyenne 2 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jin-Ding Huang	CEO & Director	2.4yrs	pas de données	pas de données
Ting-Wu Hu	Chairman	11.8yrs	pas de données	3.34% NT$ 150.8m
Chia-Hung Lee	Supervisor	9.4yrs	pas de données	pas de données
Jo Shen	Director	1.6yrs	pas de données	pas de données
Chi-Hai Lin	Supervisor	8.2yrs	pas de données	pas de données
Jien-Fu Chen	Director	7.2yrs	pas de données	pas de données
Yeu-Chuyr Chang	Independent Director	9.4yrs	NT$160.00k	pas de données
Eric Hu	Supervisor	7.2yrs	pas de données	pas de données
Yung-Lin Ma	Independent Director	4.2yrs	NT$80.00k	pas de données
Tong-Young Lee	Independent Director	4.2yrs	NT$80.00k	pas de données

7.2yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de 6492 sont considérés comme expérimentés (ancienneté moyenne 7.2 ans).

Senhwa Biosciences Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024

Senhwa Biosciences, Inc. Receives US FDA Study May Proceed Letter for the Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II Study of Silmitasertib in Children /Dearyoung Adults with Relapsed Refractory Solid Tumors

First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023)

Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022)

Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19

Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection

Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19

New minor risk - Share price stability

Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021)

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NT$143

Less than half of directors are independent

Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations

Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2)

Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020)

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment

First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020)

Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019)

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

New 90-day low: NT$162

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

New 90-day low: NT$172

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Earnings beat expectations

Third quarter 2020 earnings released: NT$1.52 loss per share

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19

New 90-day high - NT$181

First half earnings released

New 90-day high - NT$180

PDG

Titularisation

Équipe de direction

Durée moyenne de l'emploi

Membres du conseil d'administration

Durée moyenne de l'emploi